Sponsor:
M.D. Anderson Cancer Center
Code:
NCT06912763
Conditions
Fibrosis Syndrome
Lymphedema
Head &Amp; Neck Cancer
Fibrosis
Eligibility Criteria
Sex: Female
Age: 0+
Healthy Volunteers: Not accepted
Interventions
Pravastatin (drug)
Pentoxifylline
ketoprofen
Pirfenidoneone
Standard of Care (SOC)
Brief summary:
Conditions
Fibrosis Syndrome
Lymphedema
Head &Amp; Neck Cancer
Fibrosis
Study ID
NCT06912763
Start date
Aug 8, 2025
Status verified date
Jul, 2026
Completion date
Jul 31, 2031
Anticipated
Primary completion date
Jul 31, 2030
Anticipated
Eligibility Criteria
Sex: Female
Age: 0+
Healthy Volunteers: Not accepted
Enrollment
250 participants
Anticipated
Allocation
Randomized
Intervention Model
Single group
Primary purpose
Supportive Care
Arms
experimental: Treatment with Pravastatin QD
experimental: Treatment with Pentoxifylline TID + Tocopherol
experimental: Treatment with Ketoprofen TID
experimental: Treatment with Pirfenidone TID
experimental: Treatment with SoC (Control)
Interventions
Pravastatin (drug)
Pentoxifylline
ketoprofen
Pirfenidoneone
Standard of Care (SOC)
tocopherol
Primary outcome measure
Central contacts
Locations
MD Anderson Cancer Center
Recruiting
Houston, Texas, United States, 77030
Contacts
Principal Investigator:
Clifton Fuller, MD
Sponsor
M.D. Anderson Cancer Center
Last update posted
Jul 24, 2026
Last verified
Jul, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-07-24.